Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of “Moderate Buy” from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $134.30.

A number of brokerages have recently commented on ORKA. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Barclays increased their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. Guggenheim set a $200.00 target price on Oruka Therapeutics and gave the company a “buy” rating in a research report on Monday, April 27th. UBS Group boosted their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Finally, BTIG Research reaffirmed a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a research report on Monday, July 13th.

Oruka Therapeutics Stock Down 1.4%

Oruka Therapeutics stock opened at $96.51 on Friday. Oruka Therapeutics has a 12-month low of $12.84 and a 12-month high of $99.00. The business’s 50-day simple moving average is $78.73 and its 200 day simple moving average is $57.77. The stock has a market cap of $5.82 billion, a price-to-earnings ratio of -49.75 and a beta of -0.35.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. As a group, sell-side analysts expect that Oruka Therapeutics will post -2.06 EPS for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other news, Director Carl Dambkowski sold 12,583 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $70.11, for a total value of $882,194.13. Following the sale, the director owned 38,743 shares of the company’s stock, valued at $2,716,271.73. The trade was a 24.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at $64,503,670.20. The trade was a 0.19% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 188,406 shares of company stock valued at $12,019,683 over the last ninety days. 23.49% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Oruka Therapeutics

A number of large investors have recently modified their holdings of ORKA. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics in the second quarter valued at about $28,000. BNP Paribas Financial Markets raised its holdings in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after acquiring an additional 2,306 shares in the last quarter. Royal Bank of Canada raised its holdings in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in Oruka Therapeutics during the fourth quarter valued at approximately $37,000. Finally, PNC Financial Services Group Inc. acquired a new position in Oruka Therapeutics during the third quarter valued at approximately $39,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.